Literature DB >> 12406563

Expression of hyaluronate and hyaluronate synthase in human primary tumours and their metastases in scid mice.

Milan Jojovic1, Bertrand Delpech, Peter Prehm, Udo Schumacher.   

Abstract

Hyaluronate and hyaluronate synthase expression were examined in primary tumours and if present in metastatic deposits of human breast, colon, ovarian and small-cell lung cancer cell lines transplanted into scid mice using biotinylated hyaluronectin and immunohistochemical staining of hyaluronate synthase. Very intensive hyaluronate and hyaluronate synthase expression could be observed in peripheral areas of tumours derived from highly metastatic cell lines (HT29, MCF-7). Even smaller lung metastases of up to 15 cells showed typically a focal binding of hyaluronectin predominantly at the host-tumour interface of the metastases, indicating that increased expression is closely correlated with the degree of invasiveness and metastatic potential of malignant tumours.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406563     DOI: 10.1016/s0304-3835(02)00037-x

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  10 in total

Review 1.  Hyaluronic acid in digestive cancers.

Authors:  Ruo-Lin Wu; Lei Huang; Hong-Chuan Zhao; Xiao-Ping Geng
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-17       Impact factor: 4.553

2.  Versican induces a pro-metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides.

Authors:  Miranda P Ween; Katja Hummitzsch; Raymond J Rodgers; Martin K Oehler; Carmela Ricciardelli
Journal:  Clin Exp Metastasis       Date:  2010-12-12       Impact factor: 5.150

3.  The hyaluronan-related genes HAS2, HYAL1-4, PH20 and HYALP1 are associated with prognosis, cell viability and spheroid formation capacity in ovarian cancer.

Authors:  Jette Riecks; Arianna Parnigoni; Balázs Győrffy; Ludwig Kiesel; Alberto Passi; Davide Vigetti; Martin Götte
Journal:  J Cancer Res Clin Oncol       Date:  2022-06-29       Impact factor: 4.322

4.  Inhibition of Angiogenesis and Extracellular Matrix Remodeling: Synergistic Effect of Renin-Angiotensin System Inhibitors and Bevacizumab.

Authors:  Tianshu Ren; Hui Jia; Qiong Wu; Yan Zhang; Qun Ma; Dong Yao; Xudong Gao; Danni Xie; Zihua Xu; Qingchun Zhao; Yingshi Zhang
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 5.  Hyaluronan: genetic insights into the complex biology of a simple polysaccharide.

Authors:  John A McDonald; Todd D Camenisch
Journal:  Glycoconj J       Date:  2002 May-Jun       Impact factor: 2.916

Review 6.  Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.

Authors:  Miranda P Ween; Martin K Oehler; Carmela Ricciardelli
Journal:  Int J Mol Sci       Date:  2011-01-31       Impact factor: 5.923

7.  Chemotherapy-induced hyaluronan production: a novel chemoresistance mechanism in ovarian cancer.

Authors:  Carmela Ricciardelli; Miranda P Ween; Noor A Lokman; Izza A Tan; Carmen E Pyragius; Martin K Oehler
Journal:  BMC Cancer       Date:  2013-10-14       Impact factor: 4.430

Review 8.  The motile breast cancer phenotype roles of proteoglycans/glycosaminoglycans.

Authors:  Dragana Nikitovic; Katerina Kouvidi; Kallirroi Voudouri; Aikaterini Berdiaki; Evgenia Karousou; Alberto Passi; George N Tzanakakis
Journal:  Biomed Res Int       Date:  2014-07-22       Impact factor: 3.411

9.  Inverse expression of hyaluronidase 2 and hyaluronan synthases 1-3 is associated with reduced hyaluronan content in malignant cutaneous melanoma.

Authors:  Hanna Siiskonen; Mari Poukka; Kristiina Tyynelä-Korhonen; Reijo Sironen; Sanna Pasonen-Seppänen
Journal:  BMC Cancer       Date:  2013-04-05       Impact factor: 4.430

10.  The interaction between LYVE-1 with hyaluronan on the cell surface may play a role in the diversity of adhesion to cancer cells.

Authors:  Yan Du; Hua Liu; Yiqing He; Yiwen Liu; Cuixia Yang; Muqing Zhou; Wenjuan Wang; Lian Cui; Jiajie Hu; Feng Gao
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.